ReviewMolecular cell2018
CRISPR-Based Technologies: Impact of RNA-Targeting Systems.
Review in Molecular cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 172 citations in OpenAlex.
- CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review.Molecular biotechnology · 2022Pooled it
- Article
- Structural insights into C-terminus-mediated RNA target cleavage by a mesophilic prokaryotic argonaute.Nature communications · 2026Article
- Engineering multiple levels of specificity in an RNA viral vector.Nature communications · 2026Article
- Characterization of gRNA-dependent and gRNA-independent off-target binding sites of PspCas13b and RfxCas13d in mammalian cells.Nucleic acids research · 2026Article
- A versatile type VI CRISPR-based approach for targeted mGenome research · 2026Article
- Generation of IL17RB Knockout Cell Lines Using CRISPR/Cas9-Based Genome Editing.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Circular RNAs: Key Regulators of Tumor Metabolic Reprogramming and Clinical Translation.Oncology research · 2026Review
- Targeted RNA base editing for therapeutic: mechanisms and advances.Pharmaceutical science advances · 2025Review
- Review
- Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems.Pharmacological reviews · 2025Review
- CRISPR/Cas-mediated mRNA knockdown in the embryos of Xenopus tropicalis.Cell & bioscience · 2025Article
- A high-fidelity CRISPR-Cas13 system improves abnormalities associated with C9ORF72-linked ALS/FTD.Nature communications · 2025Article
- RNA Therapeutics: Bridging Discovery and Clinical Implementation.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Recent progress in prompt molecular detection of liquid biopsy using Cas enzymes: innovative approaches for cancer diagnosis and analysis.Journal of translational medicine · 2024Review
- Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing.Nature structural & molecular biology · 2024Article
- Construction and Stability of All-in-One Adenovirus Vectors Simultaneously Expressing Four and Eight Multiplex Guide RNAs and Cas9 Nickase.International journal of molecular sciences · 2024Article
- Tracking endogenous proteins based on RNA editing-mediated genetic code expansion.Nature chemical biology · 2024Article
- Structures, mechanisms and applications of RNA-centric CRISPR-Cas13.Nature chemical biology · 2024Review
- Repurposing CRISPR-Cas13 systems for robust mRNA trans-splicing.Nature communications · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
DNA-targeting CRISPR-Cas systems, such as those employing the RNA-guided Cas9 or Cas12 endonucleases, have revolutionized our ability to predictably edit genomes and control gene expression. Here, I summarize information on RNA-targeting CRISPR-Cas systems and describe recent advances in converting them into powerful and programmable RNA-binding and cleavage tools with a wide range of novel and important biotechnological and biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.